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Most neutralizing human monoclonal antibodies
target novel epitopes requiring both Lassa virus
glycoprotein subunits
James E. Robinson1, Kathryn M. Hastie2, Robert W. Cross3, Rachael E. Yenni4, Deborah H. Elliott1, Julie A. Rouelle1,
Chandrika B. Kannadka1, Ashley A. Smira1, Courtney E. Garry1,5, Benjamin T. Bradley1, Haini Yu1, Jeffrey G. Shaffer6,
Matt L. Boisen7, Jessica N. Hartnett4, Michelle A. Zandonatti2, Megan M. Rowland8, Megan L. Heinrich8,
Luis Martı´nez-Sobrido9, Benson Cheng9, Juan C. de la Torre2, Kristian G. Andersen2,10, Augustine Goba11,
Mambu Momoh11,12, Mohamed Fullah11,12, Michael Gbakie11, Lansana Kanneh11, Veronica J. Koroma11, Richard Fonnie11,
Simbirie C. Jalloh11, Brima Kargbo13, Mohamed A. Vandi11,13, Momoh Gbetuwa11,13, Odia Ikponmwosa14,
Danny A. Asogun14, Peter O. Okokhere14, Onikepe A. Follarin14,15,16, John S. Schieffelin1,17, Kelly R. Pitts7, Joan B. Geisbert3,
Peter C. Kulakoski5, Russell B. Wilson5, Christian T. Happi14,15,16, Pardis C. Sabeti18,19,20, Sahr M. Gevao21, S. Humarr Khan11,13,
Donald S. Grant11,13, Thomas W. Geisbert3, Erica Ollmann Saphire2,22, Luis M. Branco8 & Robert F. Garry4,8
Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations.
The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected
human hosts have not been identiﬁed or characterized. Here we have cloned 113 human
monoclonal antibodies (mAbs) speciﬁc for LASV glycoproteins from memory B cells of Lassa fever
survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1
receptor-binding subunit and the remaining fourth are speciﬁc for the assembled glycoprotein
complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that
neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3
require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding
afﬁnities and greater divergence from germline progenitors. Some mAbs potently neutralize all four
LASV lineages. These insights from LASV human mAb characterization will guide strategies for
immunotherapeutic development and vaccine design.
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I
nfection with Lassa virus (LASV), a member of the
Arenaviridae, results in a spectrum of illness from inapparent
infection to Lassa fever, a severe multisystem disease that often
has haemorrhagic manifestations. LASV infection is acquired
primarily via exposure to the urine and faeces of its reservoir
Mastomys natalensis, the natal mastomys or multimammate ‘rat’
(ref. 1). Tens of thousands of Lassa fever cases are estimated to
occur annually in West Africa, with Sierra Leone, Guinea, Liberia
and Nigeria reporting the highest incidences2. There are three
diverse LASV lineages in Nigeria (I–III), but a single lineage (IV)
in Sierra Leone3,4. In Sierra Leone the case fatality rate of patients
presenting while viraemic is 69% (ref. 5).
The lack of an approved therapeutic or vaccine, potential
for geographic expansion of the rodent reservoir, ease of
procurement and weaponization of the virus, and the possible
emergence of new viral strains support recommendations for
enhanced surveillance and preparedness for Lassa fever6. Human
monoclonal antibodies (mAbs) can be exploited to gain valuable
insights into immune responses to pathogens. Determining the
sites at which mAbs bind to pathogen proteins identiﬁes epitopes
recognized by the humoral immune system, and may reveal
mechanisms of immune surveillance, evasion or escape7–9.
Structural and biophysical comparisons of protective antibodies
to their germline precursors traces their ontogeny, which can
guide vaccine development10. Human mAbs also have potential
for use as immunotherapeutics, with fewer developmental steps
and regulatory hurdles than antibodies from other species that
require humanization and may elicit immune reactions11.
Arenaviruses encode a polyprotein referred to as the
glycoprotein complex (GPC), which is processed into GP1 and
GP2 and an unusual stable signal peptide (SSP)12. GP1 is
responsible for receptor binding, while GP2 mediates fusion of
the virion with a cell membrane. SSP is required for proper
processing of GPC and is retained as part of the complex13.
To date the epitopes of LASV glycoproteins that elicit protective
antibody responses in naturally infected human hosts have not
been identiﬁed or characterized. To elucidate the antigenic
structure of LASV glycoproteins, we isolated and characterized
mAbs derived from West African patients who had survived
Lassa fever and who had developed sustained antibody titres
to LASV antigens months or years into convalescence. The
dominant class of neutralizing human mAbs target novel epitopes
requiring both Lassa virus glycoprotein subunits. The elucidation
of the antigenic structure of the surface glycoproteins of LASV
can guide future efforts to derive immunotherapeutics and
vaccines.
Results
Generation of mAbs. We generated 113 molecularly cloned
human mAbs that recognize LASV GPC. These mAbs were
derived from B cells of 17 subjects with previous LASV infection
(Supplementary Table 1). Fifteen subjects were from Sierra Leone
and two were from Nigeria. All but one of the mAbs were
ﬁrst detected by enzyme-linked immunosorbent assay (ELISA)
reactivity with an unprocessed insect cell-produced recombinant
GPC (Josiah strain lineage IV) lacking the transmembrane and
intracytoplasmic domains (rGPe) as the capture antigen. The
exception was 8.9F, which did not bind to rGPe in ELISA, but was
detected by its ability to neutralize a pseudovirus expressing
LASV GPC.
LASV GPC consists of a SSP and GP1 and GP2 subunits
(Fig. 1a and Supplementary Figs 1 and 2). To deﬁne subunit
speciﬁcity of the mAbs, we used an immunoﬂuorescence assay to
test mAb reactivity with air-dried, unﬁxed smears of HEK293T
cells expressing either rGP1 or rGP2 alone, or full-length GPC
(Fig. 1b). This assay detected all mAbs, including 8.9F. No mAb
was reactive with untransfected cells. Twenty-nine mAbs were
reactive with GP1, including three neutralizing mAbs (Figs 1c
and 2). Fifty-seven mAbs recognized GP2, but none of these
exhibited neutralizing activity (Fig. 1c). Seven mAbs reacted
with peptides representing three linear epitopes in GP2
(Supplementary Fig. 3); the remaining mAbs likely recognize
conformational epitopes. Twenty-seven mAbs reacted with cells
expressing full-length GPC, but did not react with either rGP1 or
rGP2 expressed individually. Remarkably, thirteen of these anti-
GPC mAbs were neutralizing. This GPC-reactive set constitutes
the major group of neutralizing mAbs identiﬁed.
Neutralization properties of mAbs. Neutralizing activities of
mAbs were evaluated in two pseudovirus assays and in a standard
plaque reduction neutralization test (PRNT) with authentic
LASV. In all, 15 of the 113 mAbs neutralized LASV pseudo-
particles (LASVpp) expressing GPC of the lineage IV Josiah strain
(Fig. 2a and Supplementary Fig. 4). These mAbs were tested in
the same assay against LASVpp containing GPC of the three
other LASV lineages. A heat map of the IC50 and IC80 values
shows that those with the greatest potency and breadth against all
four LASV lineages were 25.10C, 12.1F, 8.9F, 37.2D, 37.7H, 25.6A
and 9.8A (Fig. 2a). The remaining mAbs showed weaker and
variable potency. 37.2G, 2.9D and NE13 had little or no activity
against the Pinneo strain (lineage I), 19.7E failed to neutralize the
A19 strain (lineage III) and 36.1F neutralized only the Josiah
strain (lineage IV).
To conﬁrm these ﬁndings, we tested a subset of mAbs for activity
against LASV lineage IV Josiah using an lymphocytic choriome-
ningitis virus (LCMV)-based pseudovirus assay and a standard
PRNT with authentic LASV. The six antibodies that were the most
potent against human immunodeﬁciency virus (HIV)-1 pseudo-
viruses (25.10C, 8,9F, 12.1F, 36.1F, 37.2D and 25.6A) were also the
most potent against LCMV-based LASV pseudoparticles and
authentic LASV although IC50 and IC80 values were somewhat
higher in LCMV-based pseudoparticle and PRNT assays (Fig. 2c).
Further, several mAbs that neutralized LASVpp either did not
neutralize authentic LASV (36.9F, NE13 and 2.9D) or showed weak
activity (8.11G, 37.2G, 9.8A and 18.5C). A signiﬁcant difference was
that 10.4B showed intermediate neutralizing activity in the PRNT,
but did not neutralize in either LASVpp system.
Cross-competition groups. Using an ELISA with ConA-captured
LASV GPC from Triton X-solubilized cells as antigen, we per-
formed cross-competition assays with the 16 LASV-neutralizing
mAbs to determine whether they recognized independent binding
sites. We identiﬁed four competition groups of neutralizing mAbs
(Fig. 2d). One is comprised of the GP1 mAbs 12.1F, 19.7E and
10.4B. The other three contain the anti-GPC mAbs. GPC-A
contains 25.10C, 36.1F and 8.11G; GPC-B includes 37.2D, 37.7H,
37.2G, 36.9F, 25.6A, 2.9D, 18.5C and NE13; and GPC-C contains
one mAb, 8.9F, which competes only with itself. Interestingly, the
anti-GP1 mAb 12.1F partially blocks 8.9F and 8.11G binding,
but 8.9F and 8.11G do not block binding of 12.1F. Several non-
neutralizing mAbs (20.5G and 38.8B) cross-compete with GPC-B
mAbs and are included in this group (Supplementary Table 1).
Non-neutralizing mAbs that react with GP1 expressed alone fail
to cross-compete with GP1-A mAbs, but variably cross-compete
with each other and recognize a cluster of epitopes tentatively
designated GP1-B. There are at least two additional groups
of non-neutralizing mAbs, GP2-A and GP2-B, that recognize
conformational epitopes on GP2. Three additional groups of
non-neutralizing GP2 mAbs that recognize linear peptides are
designed GP2-L1, -L2 and -L3.
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Immunoprecipitation of GP1 and GP2 by neutralizing mAbs.
To characterize the interactions of mAbs with LASV GPC and
its subunits, we performed immunoprecipitation assays with
lysates of GPC-expressing cells prepared either in radio-
immunoprecipitation assay (RIPA) buffer or in buffer containing
1% Triton X (Fig. 3 and Supplementary Fig. 5). Representative
GP1 mAbs (12.1F and 19.7E) or GP2 mAbs (4.1F and 13.4E)
precipitated only GP1 or GP2, respectively, from RIPA buffer
lysates, whereas the anti-GPC mAbs were non-reactive (Fig. 3a).
By contrast, anti-GPC mAbs invariably co-precipitated GP1 and
GP2 equally well from Triton X lysates (Fig. 3b). However, under
these conditions 19.7E and 12.1F also co-precipitated both
subunits, despite their known GP1 speciﬁcity. GP2 mAbs 4.1F
and 13.4E were less reactive with GP2 in Triton X lysates than in
RIPA lysates and showed minimal or no co-precipitation.
These results suggested that processed GP1 and GP2 form stable
complexes within transfected cells and that the stronger ionic and
anionic detergent mixture in RIPA buffer disrupts GP1–GP2
interactions that are critical for recognition by anti-GPC mAbs.
Dissociation of GP1 and GP2 by RIPA buffer permits greater
reactivity with the GP2 mAbs 4.1F and 13.4E.
To determine if anti-GPC mAbs could bind to one subunit
more strongly than the other, we performed immunoprecipitation
assays in which mAb–GP1–GP2 complexes formed with Triton X
lysates were exposed to the chaotropic agent sodium thiocyanate
(NaSCN) at 1.5M (Fig. 3c). As noted above, the GP1 mAbs 12.1F
and 19.7E both co-precipitated GP1 and GP2. NaSCN did not
affect precipitation of GP1 by either mAb, but eliminated GP2
reactivity, thus uncovering the preferred mAb speciﬁcity.
For the anti-GPC mAbs, two patterns were observed. In the
ﬁrst pattern, shown with 25.10C and 36.1F, NaSCN treatment did
not affect mAb binding to either subunit; band densities for GP1
and GP2 were equivalent in these on western blots. The same
pattern was observed with mAbs 36.9F, 36.7G and 18.5C
(Supplementary Figs 5 and 6). These mAbs likely bind epitopes
that bridge both subunits in a stable complex. In the second
pattern, exempliﬁed by 37.2D, 37.7H and 8.9F, NaSCN treatment
caused almost complete and equal loss of both GP1 and GP2
reactivity (Fig. 3c). mAbs 9.8A, 8.11G, 25.6A, NE13 and 2.9D
showed similar patterns (Supplementary Figs 5 and 6). These
mAbs may also bind epitopes that bridge GP1 and GP2, or that
require the complex of the two to maintain the structural integrity
of the epitope. Importantly, NaSCN treatment of immune
complexes did not uncover preferential binding to either GP1
or GP2 by these anti-GPC mAbs.
Cross-reactivities between Old and New World arenaviruses.
Cross-reactivity of a subset of mAbs was determined by
immunoﬂuorescence assay with cells expressing GPC of the four
lineages of LASV or other representative Old World (OW)
arenaviruses (Fig. 4a and Supplementary Fig. 7). mAb 19.7E (and
10.4B) bound LASV GPC from lineages I, II and IV, but failed to
bind GPC from lineage III. In agreement with its neutralizing
activity, GPC-A antibody 36.1F bound only to LASV lineage IV,
the lineage that circulates in Sierra Leone, whereas GPC-B mAbs
bound effectively to GPC from each lineage. mAbs 12.1F, 37.2D,
36.9F, 37.2G, 18,5C and 9.8A bound to GPC of LCMV, but not to
Lujo virus (LUJV) or other divergent OW arenaviruses. GP2-L1
SPase
6 kDa 44 kDa
50 kDa 41 kDa
74 kDa (uncleaved)
35 kDa 3.3B
GP1
8.4F
GP2
13.4E
GP2
25.10C
GPC
36.9F
GPC
8.9F
GPC
Linear
GP1
rGP1
GP1
rGP2
GP2
GP1
GPC
rGPe
GP2
GP1 GP2 GPC
ΔGP2
SKI1/SP1 TM
SS
P
SS
P
SS
P
SS
P
60
Neutralizing
Linear
7/57
3/29
13/27
50
40
30
N
um
be
r o
f m
Ab
s
20
10
0
GP1 GP2 GPC
a
c
b
Figure 1 | Subunit speciﬁcity of LASV mAbs. (a) The LASV GPC is synthesized as a precursor protein. Signal peptidase (SPase) cleaves the small SSP,
which remains associated with the complex. SKI protease (SK1/S1P) cleaves GPC into GP1 and GP1. A recombinant LASV (Josiah strain, lineage IV) GPC
ectodomain construct (rGPe) was expressed that substituted an uncleavable linker for the SK1 site and deleted the transmembrane and extracellular
domains. Constructs expressing recombinant SSP-GP1 (rGP1) and SSP linked to GP2 were also utilized. Molecular weights are indicated in kiloDaltons
(kDa). (b) Examples of immunoﬂuorescence assays with unﬁxed, air-dried cells expressing GP1, GP2 or GPC. All assays were performed two or more times.
Scale bar, 10mm. (c) Distribution of 113 mAbs by subunit speciﬁcity, neutralizing activity and reactivity to linear peptides.
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antibodies 25.6E, 22.5D and 8.8B showed broad cross-reactivity
with OW arenaviruses, but GP2-L3 mAb 24.6C only reacted
to LASV. 8.9F was non-reactive with LASV GPC in ﬁxed
transfected cells.
In testing by ELISA, we found that the GP1-A antibodies 10.4B
and 12.1F, as well as each of the GPC-B mAbs tested cross-react
with LCMV GPC (Fig. 4b and Supplementary Fig. 8a). However,
another GP1-A mAb (19.7E), GPC-A antibodies and most GP1-B
antibodies did not cross-react with LCMV GPC. About half of the
GP2-B antibodies tested cross-reacted with LCMV GPC. Most
mAbs recognizing conformational epitopes (GP1 and the GPC
mAbs), except a subset of GP2-B mAbs, also did not cross-react
with GPC of LUJV, a divergent OW arenavirus, or with GPC of
MACV, a New World arenavirus. In contrast, GP2-L1 and -L2
mAbs that recognize linear peptides demonstrated broad
cross-reactivity, binding GPC of LCMV, LUJV and MACV. The
GP2-L3 mAb 24.6C showed weak cross-reactivity with LCMV
GPC. Overall, mAb cross-reactivities correlated with the degree of
conservation of the putative epitopes (Supplementary Fig. 2).
Epitope mapping using deletion constructs. To map regions or
sites in GP1, GP2 and GPC that are critical for mAb binding, we
tested a panel of mAbs for reactivity with a series of deletion
mutants in full-length GPC (Fig. 5a). Given that LASV and
LCMV share 63% sequence identity and several of the con-
formationally sensitive GPC-speciﬁc antibodies cross-react with
LCMV GPC, the recently solved structure of the ectodomain of
LCMV GPC (rGPe)14 was used to model the LASV GPe
protomer and to depict the location of the deletion mutations
(Fig. 5b and Supplementary Fig. 1). In the prefusion LCMV GPe
structure, the N terminus of GP1 makes extensive interactions
with GP2, notably with the fusion loop, the T-loop, and the two
heptad repeat regions (HR1 and HR2). Deletion of the ﬁrst 16
amino acids of LASV GP1 (Daa60–75) disrupted binding by
12.1F, as well as all anti-GPC-neutralizing mAbs, while having
only minimal to modest effects on remaining mAbs tested (Fig. 5c
and Supplementary Figs 1b and 8b).
LASV GP2 is a class I viral fusion protein (VFP) that forms two
heptad repeats in the post-fusion conﬁguration15. The sequences
involved in virus:cell membrane fusion at the N terminus of GP2
(aa261–297) include a peptide (aa261–279) and a disulﬁde
bonded loop (C279–C292). Deletion of a portion of the fusion
loop (Daa280–291) resulted in complete loss of binding by the
neutralizing mAbs 8.9F, 25.10C, 8.11G and 36.1F, and diminished
binding by the neutralizing mAbs 12.1F, 37.2D and 9.8A. In the
prefusion conﬁguration of LCMV-BGP2 heptad repeat 1 (HR1) is
separated into segments that interact with GP1 and probably
contribute to GPC stability14. Deletion of HR1 (Daa311–355)
abolished binding by non-neutralizing GP2 mAbs (GP2-B) and
GP2-L1 mAbs. HR1 deletion also disrupted binding by the same
mAbs that were affected by the fusion loop deletions, suggesting
that binding of these antibodies is dependent on maintenance of
the prefusion conformation of GP2. The T-loop of GP2, between
the two heptad repeats, interacts with both the N terminus of GP1
and the fusion loop. Deletion of the T-loop (Daa365–384)
profoundly disrupted reactivity of most neutralizing GP2-B
mAbs. In addition, the T-loop deletion abolished binding by
the non-neutralizing HR1-dependent GP2-B mAbs, as well as
13.4E and 1.1B that recognize a linear epitope within the T-loop.
Deletion of the part of HR2 (Daa400–412) that interacts with the
N terminus of GP1 abolished binding of all neutralizing mAbs
except 19.7E and 10.4B, and also affected binding of the non-
neutralizing anti-GPC-B mAb 20.5G and the non-neutralizing
anti-HR2 linear epitope recognized by 24.6C GP2-L3, which
binds a peptide epitope aa400–412.
To corroborate these results we engineered a series of
GPC constructs containing increasingly larger deletions in GP2.
Deletion of the N-terminal portion of the fusion loop (DEL1,
Daa261–269) affected only 8.9F binding (Fig. 5d). Deletion of the
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Figure 2 | LASV neutralization by mAbs and assignment of competition
groups. Neutralizing activity of mAbs was evaluated in two pseudovirus
assays and by a PRNT. (a) LASVpp expressing GPC representing the four
LASV lineages (I–IV) and the HIV-1 core. (b) LASVpp expressing GPC
representing LASV lineage IV and the LCMV core. (c) PRNT. The inset
indicates the potency (heat map) for IC50 and IC80 neutralization by each of
the mAbs tested in a–c. All three pairwise correlation coefﬁcients were
signiﬁcantly different at the 5% signiﬁcance level according to both
Pearson’s and Spearman’s approaches. (d) Cross-competition analysis was
performed pairwise with biotinylated (Biot.) mAbs. The analysis places
neutralizing mAbs into four competition groups. 8.9F competes with itself
and its binding is blocked by 12.1F. Results in Fig. 2 are representative of at
least two experiments performed for each assay.
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entire fusion loop (DEL2; Daa261–297) had the same effect as the
partial fusion loop deletion discussed above. DEL3 (Daa261–311)
removed the linear epitope recognized by mAb 4.1F and other
antibodies in group GP2-L1. Binding of one mAb 7.1B (GP1-A)
was abrogated by DEL 4 (Daa261–320), which removes the ﬁrst
segment of HR1 (Supplementary Table 1). In contrast, GP2-B
mAbs bound effectively to DEL4, but did not bind to DEL5,
which also deletes half of HR1 (Daa261–328), again demon-
strating that binding of GP2-B mAbs depends on the integrity
HR1 region (Fig. 5d). Remarkably, GPC-B mAbs tolerated GP2
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Figure 3 | Immunoprecipitation with anti-GPC mAbs in RIPA buffer, Triton X-100 and Triton X-100±NaSCN. LASV mAbs indicated were used as
capture antibodies in immunoprecipitation studies employing lysates from cells expressing LASV GPs (GPC, rGP1 and rGP2). Immunoprecipitated proteins
were resolved by SDS–PAGE, transferred to nitrocellulose. Western blots were probed with mouse mAbs to either GP1 (upper gel image in each panel) or
GP2 (lower image). (a) Immunoprecipitation with the indicated mAbs was performed with cell lysates prepared in RIPA buffer. (b) Immunoprecipitation
was performed with cell lysates prepared in Triton X-100-containing buffer. (c) mAb-GPC immune complexes bound to magnetic protein A beads
were treated or not treated with NaSCN before SDS–PAGE and western blotting. Gel lanes have been reordered for clarity. Uncropped western blot images
are presented in Supplementary Fig. 6. Experiments were repeated at least twice.
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Figure 4 | Cross-reactivity of mAbs isolated from survivors of LASV lineage IV infection with glycoproteins of other arenaviruses. Cross-reactivity
of human mAbs produced after natural infection with LASV lineage IV was investigated by immunoﬂuorescence or by antibody-capture ELISA.
(a) Eukaryotic expression vectors encoding GPCs of various OW arenaviruses, including LASV lineages I–IV, LCMV and LUJV were transfected into
HEK293Tcells. Fixed cell monolayers were then incubated with LASVmAbs and mAb binding was detected by indirect immunoﬂuorescence. An expanded
panel of mAbs and OW arenavirus GPCs is presented in Supplementary Fig. 7. Scale bar, 10mm. (b) GPC from the OW arenaviruses LASV (Josiah strain,
lineage IV), LCMV, LUJV and the New World arenavirus MACV were expressed and puriﬁed. Reactivity of the indicated mAbs was assessed by ELISA.
An expanded panel of mAbs is presented in Supplementary Fig. 8a. Data are pooled from at least four independent experiments.
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deletions of up to 100 amino acids (DEL6 Daa261–340 and DEL7
Daa261–361) and their binding was not disrupted until the DEL8
(Daa261–366) mutant removed the ﬁrst few amino acids in the
T-loop formed by disulﬁde bonds between C364 and C385.
This deletion also abolished binding by the non-neutralizing
GPC-B mAbs 20.5G and 38.8B that cross-compete with
GPC-B-neutralizing mAbs. DEL9 (Daa261–377) removes a linear
epitope within the T-loop, causing loss of binding by GP2-L3
mAbs 13.4E and 1.1B. Non-neutralizing mAbs binding to GP1
(2.4F and 3.3B) and to GP2-L3 (24.6C) were not affected by any
of the GP2 deletion mutants.
Epitope mapping using site-directed mutagenesis. We carried
out site-directed mutagenesis studies to better deﬁne residues in
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Figure 5 | Mapping of putative epitopes recognized by LASV mAbs by deletion mutagenensis. Wild-type recombinant LASV GPC was engineered
with deletions of amino-acid sequences to map putative B-cell epitopes on LASV glycoproteins. (a) Location of the N-terminal (N-term) deletion of GP1,
nested deletions in GP2 and mutations that delete the fusion loop, HR1, T-loop and HR2 are indicated. Alpha helices and beta sheets are labelled according
to Hastie et al.14. (b) Location of deletions in engineered GPC are mapped to structural models of GP1 and GP2 derived from threading of the LASV GPC
ectodomain to the structure of LCMV GPC. Deletions are colour coded as in a. The location of the last amino acid of each of the nested deletions in GP is
shown as a black sphere. The inset depicts the LASV GPe structural model and interaction of the N terminus of GP1 with the fusion loop and T-loop of GP2
(see also Supplementary Fig. 2a). (c) ELISA reactivity of selected mAbs to GPC constructs containing deletions of the N terminus of GP1 and indicated
regions of GP2. ELISA was performed with GPC in Triton X lysates captured in wells coated with ConA. We normalized the binding of mAbs to each mutant
by comparing optical density values observed with each mAb reacted with mutated GPC to that observed with unmutated GPC. Values indicate per cent
binding with mutant compared with unmutated control. Mutations that resulted in binding that waso10% of binding to unmutated GPC were considered
as having a signiﬁcant effect on mAb binding. Mutations that reduced binding to 10% or less of control or 11–24% of control are highlighted. Reactivity
of GP1-B and GP2-L1, L2 and L3 mAbs with each mutant reﬂected the degree to which mutations had global effects on glycoprotein conformation.
An expanded panel of mAbs is presented in Supplementary Fig. 7b. (d) ELISA reactivity of selected mAbs to GPC constructs containing increasingly larger
deletions in GP2. An expanded panel of mAbs is presented in Supplementary Fig. 8c. The results shown are representative of multiple (n44) independent
experiments.
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GP1 that affect antibody recognition (Fig. 6a). A series of triple-
alanine substitutions in the N terminus of GP1 in full-length
GPC between amino acid residues K63 through N98 affected
individual mAbs differently (Fig. 6b and Supplementary Fig. 8c).
YEL66-68AAA and ELN71-74AAA triple mutations each
abolished binding by the same neutralizing mAbs that were
affected by deletion of aa60–75 in the N-terminal region, while
mutation of residues QTL69-71AAA had less drastic effects. The
MET75-77AAA mutation abolished binding by only mAb 36.1F.
Effects on mAb binding with AAA mutants at LMN77-79,
PLS83-84 and YIM94-96 were similar to those seen with the
fusion loop deletion mutant (Daa280–291); namely loss of
binding by 12.1F and GPC-A mAbs (36.1F, 25.10C and 8.11G),
with somewhat diminished binding to 37.2D and 9.8A. Mutants
SHH91-93AAA and HHY92-94AAA uniquely affected 12.1F
binding. Mutant VGN97-99AAA affected both 12.1F and 8.9F
binding. The residues aa91–97 are part of a beta sheet (b5) that
may be a target for the binding of these antibodies. In addition,
histidines at aa92 and 93 have been implicated in LAMP1
receptor binding by GP1 (ref. 16).
mAb19.7E neutralizes LASVpp expressing GPC of lineage IV,
but fails to neutralize LASVpp expressing GPC from lineage III
(Fig. 6b). Lineage III differs from other lineages by an LLH in
place of an IIN at positions 112–114. Altering these residues in
GP1 from lineage IV from IIN to LLN reduced the binding of
19.7E and 10.4B without affecting binding by other mAbs.
Interestingly, although 12.1F is in the same GP1-A competition
group as 19.7E and 10.4B, its binding is not affected by
this mutation. We introduced single-alanine substitutions of
additional residues in GP1 to further delineate the putative
epitopes of the GP1 mAbs (Fig. 6c and Supplementary Fig. 8d).
Mutation of residue S111 to alanine reduced the binding of all
three GP1-A mAbs 19.7E, 10.4B and 12.1F. These studies also
conﬁrmed the importance of residues adjacent to aa112 in
binding of GP1-A mAbs and suggested that aa119–129 contribute
to the binding of mAb in competition group GP1-B.
Location of putative epitopes on LASV GPC. As is the case with
the LCMV GPC structure, all potential N-linked glycosylation
sites are present on the upper face of the modelled LASV GPC,
forming a glycan shield (Fig. 7 and Supplementary Fig. 1c). The
putative epitopes recognized by mAbs of groups GP1-A, GPC-A
and GPC-B correspond to surface loops between b-sheets or
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Figure 6 | Mapping of putative epitopes recognized by LASV mAbs by site-directed mutagenesis. Wild-type recombinant LASV GPC was engineered
with altered amino-acid sequences to map putative B-cell epitopes on LASV glycoproteins. (a) Location of mutations in engineered LASV glycoproteins are
mapped to a structural model of GP1. (b) Binding of mAbs to GPC constructs in which the indicated sets of three amino acids in the amino terminus of GP1
were mutated to three alanines. ConA-capture ELISA performed as in Fig. 5; results expressed as per cent of binding to unmutated control. An expanded
panel of mAbs is presented in Supplementary Fig. 8d. (c) 19.7E fails to neutralize LASVpp expressing GPC from lineage III LASV. The sequence of lineage IV
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helical domains on the glycosylated side that are not fully
occluded by glycosylation. GP1-B, GP2-A, GP2-B and linear
epitopes GP2-L1 and L3 appear to be accessible to antibody
binding from the opposite face on GPC (180o rotation). The
linear epitope at aa361–375 recognized by 13.4E and 1.1B
(GP2-L2) and the conformational epitope of GPC-B mAbs are
comprised in part of a b-sheet that interacts with the amino
terminus of GP1.
Ontogeny of anti-LASV GP mAbs. Sequence analysis of genes
encoding the LASV mAbs revealed a signiﬁcant bias of
neutralizing mAbs for use of V3 heavy chains (IGHV3) and
lambda light chains (Fig. 8a). Neutralizing antibodies showed
a lower dissociation constant (mean of log10 KD±s.d.,
 8.94±2.62 versus  6.60±1.27; P¼ 0.044 by the Wilcoxon
Mann–Whitney test, Fig. 8b) suggesting afﬁnity maturation to
superior LASV GPC binding. Both the heavy and light chains of
non-neutralizing mAbs show moderate divergence from their
presumptive germline genes at the nucleotide level, whereas
neutralizing mAbs display signiﬁcantly lower similarities (heavy
chains, P¼ 0.012; light chains, P¼ 0.001) to germline (Fig. 8c).
Three LASV mAbs, including two neutralizing mAbs isolated
from the same donor, showed pronounced divergence from
presumptive germline genes in one or both chains (B65%
identity) (Supplementary Table 1). A correlation between
the length of complementarity-determining region (CDR)-H3
domains, which is typically the major antigen-binding domain,
and neutralization potential was not observed (Fig. 8d). CDR-H3
lengths of LASV-neutralizing mAbs were variable, ranging from
12 to an unusually long 31 amino acids (Supplementary Table 1).
The heavy chains of mAbs, but not the light chains, showed a
signiﬁcant trend (P¼ 0.012) to greater divergence from germline
with increased time between infection and peripheral blood
mononuclear cell (PBMC) collection (Fig. 8e).
Discussion
We generated and analysed a panel of 113 human mAbs directed
against LASV GPC, derived from 17 human survivors of LASV
infection in West Africa. The 16 neutralizing mAbs recognize
four distinct groups of binding sites. One group contains three
mAbs directed against the GP1 subunit. The other three groups
each contain mAbs that bind GPC, but not GP1 or GP2 alone.
Immunoprecipitation assays performed with and without
exposure of mAb-GPC immune complexes to NaSCN strongly
suggest that the anti-GPC mAbs recognize complex epitopes that
bridge the GP1 and GP2 subunits, or that require the complex of
180°
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Figure 7 | Location of putative epitopes on a structural model of LASV GPC. Antibody epitopes are mapped onto the model of the LASV GP ectodomain
monomer. (a) Ribbon view. (b) Surface view. GP1, outside putative epitopes, is coloured yellow. GP2, outside putative epitopes, is coloured white.
Epitope colour code: GP1-A and GP1-B, blue; GP2-A and GP2-B, green; GP2-L1-3, purple; GPC-A, red; and GPC-B, orange. The location of the conformational
epitope of GPC-C mAb 8.9F is unknown.
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the two to maintain the quaternary nature of the epitope. This
class of neutralizing mAbs has not been previously reported for
any arenavirus.
Mutagenesis studies guided by a pre-fusion GPC crystal
structure for the related OW arenavirus LCMV14 deﬁned
architectural features of LASV GPC required for binding by the
different mAbs. These studies point to critical interactions
between GP1 and GP2 in prefusion GPC, the maintenance of
which is necessary for binding by most neutralizing mAbs.
Notably, with the exception of GP1-speciﬁc 19.7E and 10.4B, all
neutralizing mAbs are sensitive to deletion or mutagenesis of the
N-terminal 16 amino-acid residues of GP1 and deletions of the
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Figure 8 | LASV mAbs ontogeny and binding kinetics. Antibody heavy- and light-chain constructs were sequenced and consensus immunoglobulin
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analysis and prediction software. (a) Use of heavy and light chains by neutralizing (left) and non-neutralizing mAbs. (b) Dissociation constants of
neutralizing and non-neutralizing mAbs. (c) Divergence from presumed germline genes of heavy and light chains of neutralizing and non-neutralizing
mAbs. (d) CDR-H3 lengths of neutralizing and non-neutralizing mAbs. (e) Similarity to presumed germline genes of heavy and light chains of human mAbs
as a function of time between infection and PBMC collection. Neut., neutralizing; Non neut., non-neutralizing.
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T-loop and HR2 in GP2. Deletion of the N terminus of GP1 and
mutagenesis of critical contacts between GP1 and GP2 likely
cause some degree of subunit dissociation that triggers transition
to a post-fusion conformation and disrupts exposure of
neutralizing mAb-binding sites. Mutagenesis of the fusion loop
of GP2 further subdivides GPC-neutralizing antibodies that
require both GP1 and GP2 for binding. Those mAbs in group
GPC-A are affected by fusion loop deletions or mutations, while
those in group GPC-B are signiﬁcantly less affected. Group GPC-
C contains a single mAb 8.9F with a long CDR-H3 region (31 aa).
This mAb recognizes a complex quaternary epitope that is
affected by an unusually wide variety of mutations in both GP1
and GP2.
The glycan coat of GPC has recently been implicated in
shielding LASV against the neutralizing effect of host anti-
bodies17. A model of LASV GPC derived by threading the
structure of LCMV GPC14 suggests that two putative LASV GP1
epitopes map to exposed loops between glycosylation sites on this
subunit. GP1-A mAbs that interact with one of these loops are
capable of neutralizing LASV by a yet to be determined
mechanism. The intimate interactions between the N-terminal
extension of GP1 and the fusion and T-loops of GP2 observed in
LCMV GPC14, are likely to occur in GPC of LASV and other
arenaviruses. After exposure to low pH in the endosome
arenavirus GPC, like other VFPs, undergoes extensive structural
rearrangements, which trigger fusion of the viral and cell
membranes. Gaps in the glycan shield of GPC may permit
neutralizing antibodies to interact simultaneously with the
N-terminal extension of GP1 and either the fusion loop or
T-loop of GP2, resulting in blockade of structural alterations
required for fusion. Precedence for such a mechanism by
neutralizing antibodies that bridge the two subunits of other
viral fusion proteins has been established8,18.
Although mAbs provide potent tools for epitope identiﬁcation
and characterization, relatively few reports have described murine
mAbs that react with glycoproteins of the OW arenaviruses
LCMV19–21 or LASV22. LCMV-neutralizing mAbs recognize an
epitope designated GP1-A20,23,24, which based on sequences of
neutralization escape mutants involves asparagine119 (ref. 25). It
is likely that this epitope is similar to that recognized by GP1-A
LASV mAbs. Two non-neutralizing LCMV mAbs were mapped
to the same cross-reactive linear epitope in the T-loop of LCMV
GP2 that is recognized by the GP2-L2 mAbs we describe here20.
A panel of murine mAbs against LASV glycoproteins was
reported22. Although a few were neutralizing, they were not
further characterized. Studies of mAbs to New World
arenaviruses have also been limited, but include mAb directed
against the fusion peptide of Junin virus (JUNV) envelope
glycoprotein GPC that inhibits pH-induced membrane fusion26.
Recently, Mahmutovic et al.27 determined the structure of a
neutralizing mouse mAb in complex with JUNV rGP1. The
footprint of this mAb corresponds to the putative epitope
recognized by neutralizing GP1-A mAbs.
There is no approved Lassa fever vaccine, and the only available
treatment, ribavirin, is most effective only during early infection28.
Passive transfer of survivor plasma is used as a treatment for
infection by JUNV, the causative agent of Argentine haemorrhagic
fever29. Attempts to use convalescent plasma against Lassa virus
have met with variable results30. Here we demonstrate that the
neutralizing humoral response matures over time in convalescent
Lassa fever (LF) patients. In addition to our observation that the
most effective neutralizing antibodies are directed against particular
quaternary assemblies on prefusion GPC, we also ﬁnd that
neutralizing antibodies to LASV have a higher divergence from
germline genes and higher binding afﬁnities than non-neutralizing
mAbs. Further, these studies provide the initial foundation for
understanding the molecular mechanisms of antibody development,
antibody binding and antibody-mediated neutralization of LASV in
humans. These results may facilitate development of epitope-
targeted vaccines or broadly reactive antibody-based therapeutics,
both urgently needed in a region of the world now confronted with
two co-circulating, highly pathogenic haemorrhagic fever viruses.
Methods
Ethics statement. The Tulane University Institutional Review Board, the Sierra
Leone Ethics and Scientiﬁc Review Committee and the Irrua Specialist Teaching
Hospital (ISTH) Ethics Committee approved this project. Patients were referred to
the Kenema Government Hospital (KGH) or ISTH Lassa Wards from regional
health centres or the hospitals’ general wards on the basis of suspicion of Lassa
fever. Patients were cared for by trained staffs. All adult subjects provided written
informed consent to analyse and publish laboratory and clinical data. A parent or
guardian of any child participant provided written informed consent on their
behalf.
Patient samples. Anticoagulated whole blood was obtained from healthy
LASV-seropositive adult subjects in Sierra Leone or Nigeria. PBMCs were
separated from blood on Ficoll-Hypaque and cells were cryopreserved in liquid
nitrogen at the KGH or ISTH. Samples were then transported to Tulane University
Health Sciences Center in liquid nitrogen dry shippers and ultimately stored in the
vapour phase of liquid nitrogen freezers.
Cells. The following cell lines were obtained from American Type Culture
Collection (ATCC): human embryonic kidney 293T cells (ATCC CRL-11268);
African green monkey kidney epithelial Vero cells (ATCC CCL-81); and baby
hamster kidney BHK-21 (ATCC CCL-10). These cells were grown in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal bovine serum (FBS),
2mM L-glutamine, penicillin (100Uml 1) and streptomycin (100Uml 1), and
maintained in a 5% CO2 humidiﬁed atmosphere at 37 C. TZM-bl (JC53-bl) cells
were obtained from the NIH AIDS Reagent Program, as contributed by John
Kappes and Xiaoyun Wu (University of Alabama, Birmingham, AL) and
maintained as above. TZM-bl is a HeLa cell clone genetically engineered to express
human CD4, CXCR4 and CCR5, and to contain HIV Tat-responsive reporter genes
for ﬁreﬂy luciferase (Luc) and b-galactosidase under regulatory control of the
HIV-1 long terminal repeat31. MS40L cells32, kindly provided by Xin Luo (Virginia
Polytechnic Institute, Blacksburg, VA), were maintained in Iscove’s modiﬁed
Dulbecco’s medium plus 10% FCS and antibiotics, and used for B-cell feeder
cultures. Expression of human CD40L by MS40L cells was conﬁrmed by indirect
immunoﬂuorescence assay. All cell lines tested negative for mycoplasma.
Transient stimulation of memory B cells. Cryopreserved PBMCs were thawed,
washed and suspended in medium containing 10% FCS and antibiotics. B cells
and/or memory B cells were enriched using either positive or negative selection
with immunomagnetic beads (Miltenyi, San Diego, CA). In the early phases of our
studies B cells were cultured at low cell densities (25–50 cells per well) in medium
RPMI 1640 containing 10% FCS, 2 mgml 1 R848 (InVivoGen, San Diego, CA) and
100Uml 1 IL-2 in multiple 96-well culture plates seeded with irradiated mature
human macrophages as feeder cultures33,34. In later experiments memory B-cell
fractions were co-cultured at low cell densities in Iscove’s modiﬁed Dulbecco
medium containing 10% FBS, 2 mgml 1 CpG2006, 100Uml 1 rIL-2 and
25–50 ngml 1 rIL-21, with MS40L feeder cells (5,000 cells per well) in multiple
96-well plates. MS40L was derived from a murine stem cell line (MS5) engineered
to express low levels of cell surface human CD40L (ref. 32). When used as feeder
cells MS40L cells support robust B-cell growth. Irradiation of MS40L cells was not
necessary as these cells do not overgrow the cultures. In both culture systems, fresh
medium containing growth factors was added after 7 days of culture and after each
antibody-screening procedure. Screening for antibody production was begun at
12–14 days and was repeated at 3- to 4-day intervals as necessary. rIL-2 was
obtained from the NIH AIDS Reagent Program as provided by Maurice Gately
(Hoffmann–La Roche).
Screening immunoassay. The ectodomain of LASV GPC (Josiah strain) lacking
the transmembrane domain and intracytoplasmic tail (rGPe) was expressed in
insect cells and puriﬁed by afﬁnity chromatography and gel ﬁltration. Puriﬁed
LASV rGPe was stored in aliquots at 4 C. The protein was used to coat wells of
ELISA plates at 1.25 mgml 1 in fresh 0.1M NaHCO3 for 1 h at room temperature.
Wells were washed and blocked with RPMI 1640 medium and 10% FBS for 30min.
Supernatant ﬂuids from 96-well B-cell cultures were transferred to assay plates and
incubated for 1 h at room temperature. The wells were again washed and incubated
with peroxidase-conjugated goat anti-human IgG-Fc (Southern Biotech,
Birmingham, AL) diluted 1:2,000 in PBS containing 0.5% Tween 20 and 5%
whey protein (BiPro, Le Sueur, MN). After a ﬁnal wash step, colour was developed
by the addition of 3,30 ,5,50-Tetramethylbenzidine (TMB)-H2O2 as the substrate for
peroxidase. Colour development was stopped after 3–4min by the addition of 1M
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phosphoric acid. Colour was read as absorbance (optical density) at 450 nm. In
some experiments, the LASVpp reporter infectivity assay described below was used
to screen B-cell cultures for the production of neutralizing antibodies.
Antigen capture ELISAs and mAb competition assay. Wells of ELISA plates
were coated for 1 h at room temperature with ConA (25 mgml 1 in 0.1M HEPES,
pH 7.5) and incubated with cell lysates prepared in 1% Triton X-100 as previously
described for dengue virus E proteins33. Wells were blocked with medium
containing 10% FBS. mAbs were incubated in wells for 1 h at 5 mgml 1.
Thereafter, the ELISA was completed as in the screening immunoassay. For ELISA
with D7-tagged GP1 mutants, we coated wells with the murinized mAb JR52,
which binds D7. Wells were blocked with medium plus 10% FBS and reacted
for 1 h with mAbs at 5 mgml 1. Standard ELISA procedure was followed as
described above.
For mAb competition assays, ConA-captured LASV GPC was incubated for 1 h
with 50mgml 1 of each competing unlabelled mAb or buffer. Then, biotinylated
mAbs diluted to predetermined optimal dilution were added to wells with vigorous
mixing. After 1 h wells were washed and reacted another hour with peroxidase–
streptavidin (Vector Labs, Burlingame, CA) diluted 1:1,000. Wells were washed and
ELISA was completed as in the screening immunoassay.
Peptide ELISA. Peptides were designed as overlapping 15-mers, spanning the
entire length of the LASV Josiah GPC genome (61 peptides total). Each peptide
contains one unique amino acid, with seven amino acids overlapping with the
preceding peptide and seven amino acids overlapping with the following peptide.
Peptides were synthesized by ProImmune (Oxford, UK) to 95% purity conﬁrmed
by liquid chromatography–mass spectrometry. Lyophilized peptides were
resuspended in 40% acetic acid solution as 3mgml 1 stock solutions. Final acetic
acid concentrations did not exceed 1% in assays. Nunc PolySorp 96-well plates
(Sigma-Aldrich, St. Louis, MO ) were coated with peptides at a ﬁnal concentration
of 1 mg per well in 100mM sodium bicarbonate coating buffer, pH 9.5. Plates were
incubated overnight at 4 C and washed three times with PBS-Tween. Plates were
then blocked for 60min with 250ml of blocking buffer consisting of 5% milk in
PBS-Tween, then washed as above. Each mAb was incubated in blocking buffer was
added at a ﬁnal volume of 100ml to each well. The plates were incubated for 1 h at
37 C, then washed as above. Detection was performed with 100 ml per well of
horseradish peroxidase-conjugated goat a-human IgG antibody reagent (KPL))
diluted to 1:2,500 in blocking buffer. After 1 h incubation, 100 ml to each well of
TMB-H2O2 substrate was added, and the plates were incubated for 5min. The
reaction was stopped by adding 100 ml per well of TMB stop solution and read at
450 nm.
Antibody-capture ELISA. Arenavirus rGPe used in ELISA experiments was
expressed in insect cells and puriﬁed by afﬁnity chromatography and gel ﬁltration.
Corning Costar 96-well half-area assay plates (Corning Incorporated, Kennebunk,
ME) were coated with 50 ml at a ﬁnal concentration of 0.5 mg per well in PBS. Plates
were incubated overnight at 4 C and washed three times with PBS-Tween. Plates
were then blocked for 1 h with 125ml of blocking buffer consisting of 3% BSA/PBS,
then washed as above. Each mAb was diluted to a ﬁnal concentration of 5 mgml 1
in blocking buffer was added at a ﬁnal volume of 50 ml per well. The plates were
incubated for 1 h at 37 C, then washed as above. Detection was performed with
50ml to each well of horseradish peroxidase-conjugated goat a-human IgG anti-
body (Southern Biotech) diluted to 1:2,500 in blocking buffer. After 1 h incubation,
50ml to each well of TMB-H2O2 substrate was added, and the plates were incubated
for 5min. The reaction was stopped by adding 50 ml to each well of TMB stop
solution and read at 450 nm.
Cloning and expression of human immunoglobulin genes. Cells from wells
testing positive for antibody in screening assays were collected, suspended either in
RNAlater (Ambion, Austin, TX) or guanidine lysis buffer and stored frozen for
later RNA extraction and puriﬁcation (Ambion RNAqueous-Micro Total RNA
Isolation Kit). We ampliﬁed VH, Vk or Vl genes in separate reactions from RNA
puriﬁed from stored B cells using a one step RT–PCR (Invitrogen SuperScript III
kit with Platinum Taq High Fidelity polymerase) with primer mixes designed to
amplify the different families of heavy- and light-chain genes35. For expression
vector assembly, forward primers included a 25 nucleotide non-annealing 50-tag
sequence, which was homologous to the immunoglobulin leader sequence at the
30-end of the cytomegalovirus (CMV) promoter fragment. Reverse primers were
designed to overlap the 50-end of the immunoglobulin constant region for each
vector. VH, Vk or Vl PCR products from each B-cell culture were inserted by
overlapping PCR between two DNA fragments for the construction of full-length
linear expression vectors. The upstream fragment contained the CMV promoter
and the immunoglobulin leader sequence and the downstream fragment was made
up of constant region sequences for IgG1, kappa or lambda genes followed by a
C-terminal BGH poly A sequence. Paired heavy- and light-chain full-length linear
expression vectors were co-transfected into 293T cells, and supernatant ﬂuids of
transfected cultures were tested for antibody activity in the same assays used to
screen the B-cell cultures. This step allowed rapid detection of pairs of VH and VL
chain genes that functioned together to produce antibody and also determined
which light chain was involved.
To produce mAbs, we used the In-Fusion cloning system (Clontech, Mountain
View, CA) to insert re-ampliﬁed pairs of VH and VL gene fragments into pLM2
expression plasmids similar to those described by Smith et al.36, but modiﬁed to
contain the immunoglobulin leader sequence in the linear vectors35. First,
expression plasmids were linearized by restriction enzymes acting on sites within
the multiple cloning site of plasmid (EcoRI for IgG1 and lambda, and BsiWI for
kappa). Linearized vectors were then PCR ampliﬁed with primer pairs designed to
create terminal sequences that were homologous to 50 and 30 terminal sequences
of the variable region insert fragments, allowing insertion of the VH and VL
fragments into linearized plasmids by the activity of the In-Fusion enzyme
according to the manufacturer’s instructions. The resulting plasmids were
transformed in JM109 cells. We used a previously described strategy to identify
the correct pair of VH and VL clones responsible for antibody production37.
Subsequent sequencing of multiple clones showed that only one heavy and one
light chain were capable of directing mAb synthesis. mAbs encoded by each pair of
immunoglobulin plasmids were produced by transient transfection of HEK293T
cells. mAbs were puriﬁed by Protein A afﬁnity chromatography.
Indirect immunoﬂuorescence assays. Two methods were used for testing LASV
mAbs for binding to arenavirus GPCs by indirect immunoﬂuorescence. In the ﬁrst
method, HEK293T cells were transfected with plasmids constructed to express
full-length LASV GPC, or GP1 or GP2. In preliminary studies, we established that
the use of air-dried, unﬁxed cell smears gave optimal preservation and exposure of
epitopes of GPC allowing positive recognition by all mAbs in the panel and that no
LASV mAb was reactive with untransfected HEK293T cells. Cells were collected at
36–40 h post transfection and mono-dispersed in PBS. Cell smears were made from
slurries of cells applied in 1–2 ml volumes to wells of polytetraﬂuoroethylene
printed 10 or 24 well multi-test slides (Electron Microscopy Sciences, Hatﬁeld, PA).
Cell smears were air-dried for at least 10min, blocked brieﬂy with RPMI-10% FCS
and incubated with 20 ml of mAbs diluted in RPMI-10% FCS for 30–45min at
room temperature in a moist chamber. Slides were washed in PBS and then
incubated with ﬂuorescein isothiocyanate (FITC)-anti-human IgGFc (1:50 dilution,
Southern Biotech, Birmingham, LA) for 45min. Slides were again washed with
PBS, mounted with Vectashield under glass coverslips and examined under a
Nikon epiﬂuorescence microscope with  40 objective.
In the second method, HEK293T cells transfected in 48-well culture plates with
GPC-expressing plasmids were ﬁxed for 15min in 4% formaldehyde, permeabilized
with 0.2% Triton X-100 and blocked with 2.5% bovine serum albumin. Fixed-cell
monolayers were then incubated with LASV mAbs, or with the following control
murine mAbs: 36.1 (LCMV GP-1)38; L52-74-7A (LASV GP-1)39; or 83.6
(OW arenavirus cross-reactive GP-2)20 for 1 h at room temperature. Slides were
washed with PBS and then incubated with either FITC-conjugated anti-human
(1:250 dilution, Jackson ImmunoResearch, West Grove, PA) or FITC-conjugated
anti-mouse (1:140 dilution, Dako) secondary antibodies for 1 h at room
temperature. After three washes with PBS, cells were examined under a Leica
ﬂuorescence microscope and photographed (Cooke Sensicam QE) with a  20
objective.
Immunoprecipitation. Cryopreserved GPC-expressing cells were thawed, washed
and suspended in buffer contain 0.1% BSA. In one immunoprecipitation format,
mAbs were incubated for 30min with clariﬁed lysates of cells expressing GPC
prepared either in RIPA buffer (Sigma # R0278 containing 150mM NaCl, 1.0%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS and 50mM Tris (pH 8.0))
or 1% Triton X in PBS. Halt Protease Inhibitor Cocktail (Pierce, Rockford, IL) was
added to the lysis buffers and immune complexes were captured on magnetic
protein A beads (Pierce, Rockford, IL or Thermo-Fisher, Waltham, MA).
In a second format, mAbs were ﬁrst captured on Protein A magnetic beads and
washed mAb-bound beads were then incubated 30min with RIPA or Triton X
lysates of GPC-expressing cells. In both methods beads containing bound immune
complexes were washed 8–10 times in round bottom 96-well plates with RIPA
buffer containing 0.2% SDS by repeated capture on an EpiMag HT (96-Well)
Magnetic Separator (Epigentek, Farmingdale, NY) and vigorous resuspension in
RIPA buffer on a Genie plate shaker (VWR, Radnor, PA).
Beads in each well were suspended in 50 ml NuPage Sample buffer without
reducing agents and heated 10min at 75 C to elute bound proteins.
Immunoprecipitated proteins were resolved in duplicate gels by electrophoresis in
pre-cast NuPAGE 10% Bis–Tris gels, according to the manufacturer’s speciﬁcations
(Novex, San Diego, CA). Proteins from each gel were electrophorectically
transferred to nitrocellulose membranes in the iBlot Dry Blotting (Thermo-Fisher,
Walthan, MA) apparatus. In some experiments, Protein A beads with captured
immune complexes were exposed to RIPA buffer containing 1.5M NaSCN before
the bound complexes were eluted for PAGE and western blotting analysis.
Duration of exposure to NaSCN varied from 1 h to overnight.
Proteins eluted from Protein A beads in immunoprecipitation experiments were
resolved by SDS–PAGE in 10% NuPAGE gels and transferred to nitrocellulose in
XCell blot modules (Invitrogen, Carlsbad, CA). Blotted membranes were blocked
for 1 h or overnight in PBS containing 5% non-fat dry milk and placed in a MPX
multi-channel blotter apparatus. mAbs at 5 mgml 1 in 5% milk containing 0.5%
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Tween-20 were incubated in individual channels for 1 h. For each pair of blotted
membranes, one was incubated 1 h with a mixture of murinized mAbs speciﬁc for
LASV GP1 at 2 mgml 1; the other was incubated for 1 h with a mixture of
murinized mAbs speciﬁc for LASV GP2 at 2 mgml 1. Blots were washed with
PBS-0.5% Tween and incubated for an additional hour with 1:10,000 dilution of
IRDye 680RD Goat anti-mouse IgG (Hþ L) (LI-COR Biosciences, Lincoln, NE).
The membranes were then washed extensively and scanned in and Odyssey
Infrared Imager (LI-COR Biosciences, Lincoln, NE).
Images in Fig. 3 and Supplementary Fig. 5 show that results of the
immunoprecipitation experiments have been cropped and lanes have been
rearranged for clarity of presentation. Full-size western blot images containing all
lanes in their original order are presented in Supplementary Fig. 6.
Conversion of human mAb IgG1 heavy chains to murine IgG2a. To create
reagents for probing western blots from immunoprecipitation experiments we
replaced the human heavy-chain constant regions of several human IgG1 mAbs
with murine IgG2a heavy chains. This allowed use of anti-murine IgG secondary
antibody reagents without cross-reactivity with the human IgG mAbs used in
immunoprecipitation. The murine IgG2a constant region in an expression plasmid,
kindly provided by Yongjun Guan (University of Maryland), was PCR ampliﬁed
and the PCR product was then inserted into linearized human mAb heavy-chain
expression vectors. These vectors were subjected to a PCR, which in effect removed
the human IgG constant region and created terminal sequences that overlapped the
nucleotide sequences of the murine IgG2a insert. Following the methods described
by Benoit et al.40 we inserted the murine IgG2a PCR product into the linearized
vector using the In-Fusion ligase independent cloning method (Clontech,
Mountain View, CA).
Expression of recombinant proteins. Eukaryotic expression vectors based on
pCAGGS encoding full-length cDNAs of LASV lineage IV (Josiah, NP_694870)
and LCMV GPCs were previously described by Rodrigo et al.41. Similar plasmids
for expression of GPC from LASV lineage I (LP strain, CDC specimen 812285,
AAF86701), LASV lineage II (803213 strain; CDC specimen 810801, AAF86703),
LASV lineage III (GA391 strain; CDC specimen 806791, P17332), Mobala virus
(MOBV, YP_516226), Mopeia virus (MOPV, YP_170705), Merino Walk virus
(MEWV, YP_009019200) and LUJV (CDC specimen 812096, NC_012776) were
generated by cloning full-length cDNA encoding each GPC into the pCAGGS
plasmid. Each cDNA was PCR ampliﬁed from RNA extracted from infected cells
and inserted into the pCAGGS plasmid. In addition, full-length GPC cDNA from
LASV Josiah strain and three other LASV strains were cloned into pLM2, a
PBR322-based vector, which we routinely use for mAb heavy- and light-chain
expression as described above. Arenavirus rGPe (LCMV HPI AJ297484.1,
LUJVNC_012776 and MACV Carvallo AY571904) used in other ELISA
experiments was expressed from synthetic genes in insect cells and puriﬁed by
afﬁnity chromatography and gel ﬁltration.
Mutagenesis of LASV glycoproteins. Using site-directed mutagenesis,
we constructed a series of mutants of full-length LASV GPC Josiah in which
progressively longer segments of GP2 from the N terminus were deleted, while
leaving GP1 intact. Deletion mutants that removed the N-terminal 16 amino acids
of GP1 (aa60–75), or deleted the fusion loop (aa280–291), the HR1 regions
(aa311–355), the T-loop (aa365–384), or part of HR2 (aa400-412) in GP2, were
similarly constructed. Triple-alanine substitutions were also introduced by PCR
mutagenesis into the N terminus of GP1 in the full-length GPC vector from
residues K63 through N93.
A plasmid (pLM2-GP1-D7) for expression of GP1 alone was created by deletion
of GP2 (aa260–491) from full-length GPC and replacing it with the D7 epitope tag
(APTKAKRRVVQREKR), representing the conserved C terminus of HIV-1 gp120
(ref. 42). This epitope is recognized by sheep antibody D7324 (Aalto Scientiﬁc),
which is widely used in gp120 capture ELISAs in HIV studies43 and is also
recognized by a murinized mAb, JR-52, described below. HEK293T cells
transfected with SP-GP1-D7 efﬁciently produced secreted GP1, which was quite
stable. We used this plasmid to introduce a series of single-alanine substitutions
into GP1. Primers used for PCR mutagenesis were designed along the principles
described by Liu and Naismith44. The presence of the correct mutations was
conﬁrmed by sequencing.
Plasmids expressing GPC with these mutations were transfected in 293T cells,
and mAbs were tested for binding to ConA-captured glycoproteins from Triton X
lysates of transfected cells. A standard panel of neutralizing and non-neutralizing
mAbs was tested, which allowed an assessment of the overall expression levels of
each mutant. A deletion or mutation that reduced binding of mAbs by 490%
compared with binding to unmutated control GPC was considered to have a
critical effect. To assure that the deletions did not induce global structural effects,
it was also necessary to show that several groups of non-neutralizing mAbs
maintained normal or minimally affected binding activity to each mutant
compared with unmutated GPC.
To test mAb binding to GP1-D7 and alanine mutants, we coated wells with a
murinized rhesus mAb, JR52 (a gift of Yongjun Guan, University of Maryland),
which binds the D7 epitope. mAbs were incubated with JR52-captured GP1 or
mutant GP1, and their binding was assessed with a peroxidase-conjugated goat
anti-human IgGFc in a standard ELISA format.
Pseudovirus assay. We prepared Lassa pseudoviruses (LASVpp) capable of a
single round of replication by co-transfection of HEK293T cells with LASV GPC
plasmids and pSG3Denv, encoding the envelope-deﬁcient core of HIV-1 (ref. 31).
These LASVpp are readily assayed in TZMbl cells31,45, a HeLa cell derivative that
contains integrated luciferase and b-galactosidase genes under regulatory control of
an HIV-1 LTR, which is activated by HIV-1tat after virion entry. The method to
produce pseudoparticles was the same as used previously for generating HIV-1
pseudoviruses46. HEK293T cells were plated in T75 ﬂasks and grown overnight
before transfection with 10 mg of LASV GPC expression plasmids and 10 mg of
pSG3. Supernatant ﬂuids containing LASVpp were collected at 72 h after
co-transfection, clariﬁed by centrifugation, ﬁltered and frozen in aliquots  80 C
for later use. For determination of pseudovirus titres, monolayers of 50,000 TZMbl
cells per well in black 96-well plates were infected with serial dilutions of virus
stocks. Luciferase activity in the cultures was measured at 48 or 72 h after
inoculation using a commercially available kit (Promega BriteGlo). Luminescence
was measured with a Wallac 1420 Multilabel Counter (PerkinElmer, Waltham, MA).
The neutralizing activities of puriﬁed mAbs were determined by incubating
mixtures of LASVpp stocks at predetermined optimal dilutions with serial dilutions
of each mAb. The assay was then performed exactly as discussed above, and the per
cent inhibition of viral replication at each antibody dilution was determined. We
also used the LASVpp assay to screen for neutralizing antibodies. This involved
incubating supernatant ﬂuids from B-cell cultures with LASVpp in black 96-well
culture plates. TZMbl cells were added to a ﬁnal density of 5 103 cells in each
well and the plates were incubated for 48–72 h. Neutralization was assessed by
analysing the amount of luciferase produced from the pseudovirus-infected cells.
Neutralization activity was deﬁned as450% reduction in luciferase activity after a
single-round infection.
LCMV-based pseudoparticle preparation. In a second system LASV or LCMV
GPC was pseudotyped with rLCMV GPC/GFP41. Vero and BHK-21 cell lines
stably expressing LCMV or LASV GPCs were maintained in complete media
supplemented with hygromycin B (250 mgml 1). Single-cycle infectious
recombinant LCMV (Armstrong strain; ARM5-3b) expressing the green
ﬂuorescent protein, GFP (rLCMVDGPC/GFP) pseudotyped with LCMV or
LASV GPC (pLCMV or pLASV, respectively) were propagated in BHK-21 cells
constitutively expressing LCMV or LASV GPC by infecting at multiplicity of
infection of 0.01 and collecting the tissue culture supernatants at 72 h post
infection. Virus titres of stocks were determined by immunofocus assay
(ﬂuorescent forming units) in GPC-expressing Vero cells.
Microneutralization assays using the pLASV and pLCMV have been previously
described41. Brieﬂy, a predetermined amount of virus to obtain 75–100%
GFP-positive cells at 48–72 h post infection was pre-incubated with twofold
dilutions of the LASV mAbs at 37 C for 90min. LCMV GPC-expressing Vero cells
(96-well plate format, 104 cells per well, triplicates) were then infected with the
virus/antibody mix at 37 C for 90min. The immune complexes were then
removed and infection was maintained in normal media at 37 C. At 48–72 h post
infection, cells were monitored for GFP expression using a ﬂuorescent microscope.
GFP intensity was measured with a microplate reader (Beckman Coulter, Pasadena,
CA). Virus inoculum in the absence of LASV mAbs was used as negative control to
set up 100% GFP expression. Per cent neutralization was ﬁtted on a sigmoidal
dose–response curve using the GraphPad Prism software and used to calculate the
EC50 of each LASV mAb.
Plaque reduction neutralization test. To assess neutralizing activity of mAbs,
a standard PRNT with infectious LASV was performed under BSL-4 conditions47.
A standard amount of LASV (B100 plaque-forming units) was incubated for
60min with serial twofold dilutions of each mAb in Earle’s Minimal Essential
Medium, 1% Pen/Strep and 1 glutamax containing 10% guinea pig complement
(Rockland, Limerick, PA). After incubation, these reaction mixtures were assayed
for residual infectivity as measured by plaque-forming units47. The mixture was
used to inoculate Vero 76 cells for 60min. The inoculum was removed and cells
were overlaid with an agar medium and incubated for 4–6 days at 37C. Cells were
stained with neutral red for 24 h and plaques were counted. End-point titres
were determined through standard 4-parameter logistic regression analysis and
represented as the dilution of antibody, which neutralized 50% of the plaques.
For these assays we used a low-passage LASV Josiah virus stock, which was kindly
provided by Tom Ksiazek (University of Texas Medical Branch-Galveston, TX),
and originated from CDC Lassa-Josiah CDC number 057562. This strain was
originally isolated from a human clinical specimen that was passed once in Vero
cells and twice in Vero E6 cells.
Modelling of LASV GPC. SWISS-MODEL (http://swissmodel.expasy.org/), an
automated system for homology modelling the three-dimensional structure of a
protein from its amino-acid sequence48, was use to thread aa59–424, which
comprise the ectodomain of LASV GPC (Josiah strain, lineage IV), on to the
recently determined structure of LCMV GPe14. The ﬁnal LASV GPe model has an
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RMSD of 0.84 as compared with LCMV GPe with a GMQE of 0.81 (Global Model
Quality Estimation where identical structures have a GMQE of 1). Location and
orientation of the N-linked glycan were modelled based on the location of the
cognate glycan in the LCMV GPe structure template. The exception to this is the
glycan at N99, which does not exist in LCMV GPe. Instead, this glycan was
modelled using Coot49 to minimize clashes with surrounding residues.
To assist sequence alignments we used PredictProtein (https://www.
predictprotein.org), a meta-service that provides multiple sequence alignments,
and predicts aspects of protein structure such as secondary structure, solvent
accessibility, transmembrane helices and strands, coiled-coil regions, disulﬁde
bonds and disordered regions. PyMOL (https://www.pymol.org), an open-source,
user-sponsored, molecular visualization system created by Warren Lyford
DeLano and currently commercialized by Schro¨dinger, Inc., was used to produce
three-dimensional images.
In silico analysis of antibody sequences. Antibody heavy and light-chain con-
structs were sequenced by the Sanger method (Agencourt Bioscience Corporation,
Beverly, MA). Sequence accuracy was veriﬁed using multiple independent clones
for each unique heavy and light chains. Consensus immunoglobulin sequences
spanning framework 1 through 4, and encompassing CDRs 1–3 were subjected to
in silico analysis using the IMGT/V-QUEST online database search and analysis
software package, reference directory release 201515-3 (8 April 2015), employing a
full complement of analytical parameters and compared with the human (Homo
sapiens) immunoglobulin set50. Additional analyses were performed using the
abYsis integrated antibody sequence analysis and prediction Software package
(http://www.bioinf.org.uk/abysis/). The analysis reported in this manuscript used
the Kabat numbering scheme to derive and characterize framework and CDR
domains in antibody sequences.
Kinetics of LASV mAb binding. mAb-binding analysis done on a Biacore 3000
(GE Healthcare, Little Chalfont, United Kingdom). A GE Healthcare Sensor Chip
CM5 was coated with 15 mgml 1 anti-FLAG antibody (Sigma-Aldrich, St. Louis,
MO). Interaction analysis was performed by injection of LASV recombinant
glycoproteins or FLAG protein (Sigma-Aldrich, St. Louis, MO) at concentrations
that produced a response between 50 (Rmin) and 185 (Rmax) ‘response units’. Flow
was 5 ml min 1 in a HEPES-EP buffer, pH 7.5. Once the proteins were covalently
immobilized, the ﬂow rate was changed to 15 ml min 1. Varying concentrations of
LASV mAbs were then injected and kinetic parameters determined using a bivalent
binding curve.
Statistical analysis. Categorical data were summarized as frequencies and
percentages (a) and continuous data were summarized as medians and their
respective interquartile ranges (b–d). Data were considered in their individual
form for those cases where monotonic trend was of primary interest. Statistical
comparisons of categorical variables (a) were carried out using Fisher’s exact test,
and those comparisons for continuous variables (b–d) were carried out using the
Wilcoxon Mann–Whitney test. Kendall’s tau test for trend was used to assess
monotonic trends in individual data (e). Analyses were two-tailed and carried out
using the SAS System (version 9.3; SAS Institute, Inc., Cary, NC). P values were
expressed in their exact forms, and the signiﬁcance threshold was set at Po0.05.
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